Effect of Subcutaneous Methoxy Polyethylene Glycol-epoetin Beta on Anemia and Nutritional Indices in Peritoneal Dialysis Patients |
Kim, Kyung Sook
(College of Pharmacy, Chungbuk National University)
Lee, Jun Seop (Department of Pharmacy, Chungbuk National University Hospital) Kim, Hye-Young (Department of Internal Medicine, College of Medicine, Chungbuk National University) Lee, Myung Koo (College of Pharmacy, Chungbuk National University) |
1 | Roger SD, Locatelli F, Woitas RP, et al., C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant, 2011; 26(12): 3980-3986. DOI ScienceOn |
2 | Grzegorzewska AE, Leander M. Lymphocyte subset counts in continuous ambulatary peritoneal dialysis patients in relation to administration of recombinant human erythropoietin and angiotensin-converting enzyme inhibitors. Adv Perit Dial 2002; 18: 6-11. |
3 | Paskalev E. Influence of anemia treatment of malnutrition in patirnts on hemodialysis. Nephron 2000; 86(2): 215-216. DOI ScienceOn |
4 | 서정철, 김혜영, 양용모, 등. 혈액투석 환자에서 erythropoietin 의 피하주사와 저용량 androgen의 병용투여가 빈혈과 영양지표에 미치는 효과. 대한신장학회지 2001; 20(1): 67-74. |
5 | NKF-KDOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2000; 35(6): S17- S104. DOI ScienceOn |
6 | Klinger M, Arias M, Vargemezis V, et al., Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50(6): 989-1000. DOI ScienceOn |
7 | Canaud B, Mingardi G, Braun J, et al., Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23(11): 3654-3661. DOI ScienceOn |
8 | Levin NW, Fishbane S, Canedo FV, et al., Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370(9596): 1415-1421. DOI ScienceOn |
9 | Locatelli F, Villa G, de Francisco AL, et al., Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007; 23(5): 969-979. DOI ScienceOn |
10 | Sulowicz W, Locatelli F, Ryckelynck JP, et al., Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2(4): 637-646. DOI ScienceOn |
11 | Macdougall IC, Walker R, Provenzano R, et al., C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3(2): 337-347. DOI ScienceOn |
12 | Kessler M, Martinez-Castelao A, Siamopoulos KC, et al., C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodial Int 2010; 14(2): 233-239. DOI ScienceOn |
13 | National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(5): S16-S85. DOI |
14 | Astor BC, Muntner P, Levin A, et al., Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162(12): 1401-1408. DOI ScienceOn |
15 | 신승희, 지은희, 이영숙, 등. 혈액투석 환자의 빈혈관리에서 erythropoietin 반응에 영향을 미치는 인자. 한국임상약학회지 2011; 21(2): 122-130. |
16 | 이윤덕, 김경임, 김영주, 등. 항암치료로 인한 빈혈의 치료에서 Epoetin Alpha 주일회요법과 주삼회요법의 약효 비교 연구. 한국임상약학회지 2009; 19(2): 146-152. |
17 | Snyder JJ, Foley RN, Gibertson DT, et al., Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol 2004; 15(1): 174-179 DOI ScienceOn |
18 | Carrera F, Lok CE, de Francisco A, et al., Maintenance treatment of renal anemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010; 25(12): 4009-4017. DOI ScienceOn |
19 | 임춘수. 만성 신질환 환자에서 빈혈의 치료. 대한신장학회지 2006; 25(2): S551-S558. |
20 | Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004; 65(5): 1864-9. DOI ScienceOn |
21 | Nicoletta P, Bernardini J, Dacko C, et al., Compliance with subcutaneous erythropoietin in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 90-92. |
22 | 안승찬, 최승옥, 신승준, 등. 혈액투석중인 만성신부전 환자의 빈혈에 관한 연구. 대한신장학회지 1994; 13(4): 769-775. |
23 | Eschbach JW, Egrie JC, Downing MR, et al., Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316(2): 73-78. DOI ScienceOn |
24 | Winearls CG, Oliver DO, Pippard MJ, et al., Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet 1986; 2(8517): 1175-1178. |
25 | Nissenson AR, Swan SK, Lindberg JS, et al., Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40(1): 110-118. DOI ScienceOn |
26 | Locatelli F, Canaud B, Giacardy F, et al., Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18(2): 362-369. DOI ScienceOn |
27 | Curran MP, McCormack PL. Methoxy polyethylene glycolepoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008; 68(8): 1139-1156. DOI ScienceOn |
28 | Jarsch M, Brandt M, Lanzendorfer M, et al., Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacol 2008: 81(1): 63-69. DOI ScienceOn |
29 | Panchapakesan U, Sumual S, Pollock C. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (continuous erythropoietin receptor activator). Int J Nanomed 2007; 2(1): 33-38. DOI ScienceOn |
30 | Fouque D, Pelletier S, Mafra D, et al., Nutrition and chronic kidney disease. Kidney Int 2011; 80(4): 348-357. DOI ScienceOn |
31 | McCarthy JT. A practical approach to the management of patients with chronic renal failure. Mayo Clin Proc 1999; 74(3): 269-273. DOI ScienceOn |
32 | Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990; 300(6724): 573-578. DOI ScienceOn |
33 | 강재영, 정두련, 김경조, 등. r-HuEPO 투여후 복막투석 환자의 영양지표의 변화에 대한 연구. 대한신장학회지 1995; 14(2): 205-212. |
34 | Tarng DC, Huang TP, Doong TI. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin. Nephron 1998; 78(3): 253-259. DOI ScienceOn |
35 | Gandra SR, Finkelstein FO, Bennett AV, et al., Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis 2010; 55(3): 519-534. DOI ScienceOn |